Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/75025
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Navarro, Eduardo | en_US |
dc.contributor.author | Alonso, S. J. | en_US |
dc.contributor.author | Navarro Garcia, Ricardo | en_US |
dc.date.accessioned | 2020-10-27T09:29:50Z | - |
dc.date.available | 2020-10-27T09:29:50Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.issn | 1741-427X | en_US |
dc.identifier.other | Scopus | - |
dc.identifier.other | WoS | - |
dc.identifier.uri | http://hdl.handle.net/10553/75025 | - |
dc.description.abstract | Elenine is the aglycone of elenoside, a cytotoxic arylnaphthalene lignan (NSC 644013-W/1) derived from Justicia hyssopifolia. (Family: Acanthaceae). Elenoside is a -D-glucoside, with a similar chemical structure to etoposide, exhibiting central depressant activity. In the present study, elenine was given to mice and rats at doses of 10, 20, and 40mg/kg. Acute toxicity (24h) and general behaviour in mice was studied as well as its effects on muscular relaxant activity, locomotor activity (Varimex test), and the open-field test and were compared with 10mg/kg of chlorpromazine. Elenine produced a reduction in the permanence time in muscular relaxant activity (traction test). Spontaneous activity was lower in the Varimex test. The ambulation and rearing were lower compared with the control group, and an increase in boluses was observed in the open-field test. Thus, it can be concluded that elenine has central sedative effects at lower doses than those used with elenoside and has a possible application in conditions of anxiety. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Evidence-Based Complementary and Alternative Medicine | en_US |
dc.source | Evidence-based Complementary and Alternative Medicine [ISSN 1741-427X], v. 2011 | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject.other | Sex-Differences | - |
dc.subject.other | Elenoside | - |
dc.subject.other | Lignans | - |
dc.title | Toxicity and neuropharmacological effects of elenine | en_US |
dc.type | info:eu-repo/semantics/Article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1155/2011/312524 | en_US |
dc.identifier.scopus | 80052744981 | - |
dc.identifier.isi | 000293411100001 | - |
dc.contributor.authorscopusid | 56273603700 | - |
dc.contributor.authorscopusid | 7102615168 | - |
dc.contributor.authorscopusid | 7202829137 | - |
dc.identifier.eissn | 1741-4288 | - |
dc.relation.volume | 2011 | en_US |
dc.investigacion | Ciencias de la Salud | - |
dc.type2 | Artículo | en_US |
dc.contributor.daisngid | 1970623 | - |
dc.contributor.daisngid | 1674878 | - |
dc.contributor.daisngid | 5501662 | - |
dc.description.numberofpages | 10 | en_US |
dc.utils.revision | Sí | - |
dc.contributor.wosstandard | WOS:Navarro, E | - |
dc.contributor.wosstandard | WOS:Alonso, SJ | - |
dc.contributor.wosstandard | WOS:Navarro, R | - |
dc.date.coverdate | Septiembre 2011 | en_US |
dc.identifier.ulpgc | Sí | - |
dc.description.sjr | 0,786 | |
dc.description.jcr | 4,774 | |
dc.description.sjrq | Q1 | |
dc.description.jcrq | Q1 | |
dc.description.scie | SCIE | |
item.grantfulltext | open | - |
item.fulltext | Con texto completo | - |
crisitem.author.fullName | Navarro Garcia, Ricardo | - |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.